Home > Cardiology > ACC/WCC 2020 > Atrial Fibrillation/Acute Coronary Syndrome > TWILIGHT sub-study: complex PCI patients

TWILIGHT sub-study: complex PCI patients

Presented By
Prof. G. Dangas, Icahn School of Medicine at Mount Sinai, USA

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
ACC 2020
Trial
TWILIGHT
New data from a post-hoc analysis of the TWILIGHT trial showed that, in patients who underwent a complex percutaneous coronary intervention (PCI) , ticagrelor monotherapy after an initial 3 months of dual antiplatelet therapy (DAPT) with ticagrelor plus aspirin was associated with significantly lower clinically relevant bleeding without increasing the risk of ischaemic events compared with continuing the DAPT. The TWILIGHT-COMPLEX sub-study was presented by Prof. George Dangas (Icahn School of Medicine at Mount Sinai, USA) and published simultaneously [1,2]. The original randomised, double-blind, placebo-controlled TWILIGHT trial recently determined that dropping aspirin after 3 months of DAPT with ticagrelor following PCI is associated with lower rates of bleeding but no increased risk ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on